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S U M M A R Y
A 56-year-old woman with ankylosing spondylitis, treated for 3 months with inﬂiximab, developed
miliary tuberculosis with mediastinal lymphadenopathies and brain and splenic lesions. After initial
improvement under anti-tuberculous therapy, she suffered an unexpectedly prolonged paradoxical
worsening with several episodes of lymphadenopathy, including life-threatening ones, over a period of
more than 14 months of follow-up. The outcome was favorable as a result of corticosteroid and surgical
treatments. This phenomenon reﬂects a paradoxical reaction precipitated by inﬂiximab withdrawal.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Inﬂiximab is a monoclonal antibody inhibitor of tumor necrosis
factor-alpha (TNF-a) used for the treatment of rheumatoid
arthritis, spondylarthritis, and Crohn’s disease. However, it
increases the risk of opportunistic infections, particularly tuber-
culosis (TB).
Worsening of pre-existing TB lesions or the appearance of new
TB lesions in patients whose state has initially improved with anti-
TB therapy deﬁnes a paradoxical reaction to anti-TB treatment.1
Most cases have been described in HIV patients2–4 for whom
antiretroviral therapy was initiated simultaneously or within two
months after starting anti-TB treatment. Cases occurring after
inﬂiximab therapy have rarely been reported.1,5,6
We report the case of a patient who experienced a paradoxical
reaction that lasted more than 14 months after inﬂiximab therapy
and present a review of the literature to describe this phenomenon.
2. Case report
A 56-year-old woman suffering from ankylosing spondylitis
was treated with inﬂiximab 5 mg/kg (275 mg) in November 2004.* Corresponding author. Tel.: +33 673160891.
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doi:10.1016/j.ijid.2010.03.002The second and third infusions were administered two and four
weeks later.
Her grandfather had had pulmonary and osteoarticular TB in
1953; her tuberculin skin test (TST) before starting inﬂiximab was
positive (10 mm), but she received no anti-TB treatment.
At the end of January 2005, she complained of fever, cough,
chest pain, sweats, weight loss, and headaches. A physical
examination was normal except for a temperature of 38.2 8C.
Chest and abdominal computed tomography (CT) scans showed
miliary lesions, mediastinal lymphadenopathies, and splenic
nodules. Magnetic resonance imaging revealed three brain
nodules. The cerebrospinal ﬂuid was normal; a mycobacterial
culture was sterile. HIV serology was negative. Despite negative
sputum smears for acid-fast bacilli, a four-drug regimen was
started: rifampin (600 mg/day), isoniazid (250 mg/day), pyrazi-
namide (1500 mg/day) and ethambutol (750 mg/day). Inﬂiximab
was discontinued; long-term sputum cultures grew pan-sensitive
Mycobacterium tuberculosis. From April 2005, only rifampin and
isoniazid were prescribed.
In May 2005, she developed an acute, inﬂammatory, right
supraclavicular lymphadenopathy measuring 5  4 cm (Figure 1);
standard and mycobacterial cultures of its purulent liquid content
were negative. It diminished in size after adjunctive prednisone
(1 mg/kg/day) therapy. The patient was re-hospitalized three
months later, in July 2005, for respiratory distress, chest pain, and
facial edema. A CT scan showed cervical and mediastinalses. Published by Elsevier Ltd. All rights reserved.
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Figure 1. Acute inﬂammatory right supraclavicular lymphadenopathy appeared
four months after starting anti-TB treatment.
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cava without thrombosis. Tinzaparin and methylprednisolone
(500 mg/day for 3 days) gave substantial relief; prednisone was
progressively tapered from 120 to 20 mg/day four months later,
while anti-TB therapy was continued.
In March 2006, despite her regimen of rifampin, isoniazid and
prednisone (20 mg/day), her right supraclavicular lymphadenopa-
thy reappeared, reaching 3–4 cm in size, and was surgically
excised. Histopathological examination revealed caseating gigan-
tocellular granulomas; cultures were negative. Two months later,
another cervical lymph node, measuring 2 cm, appeared and was
resolved with prednisone (60 mg/day for 2 weeks). Anti-TB
treatment was stopped in June 2006.
In January 2008, a new cervical lymphadenopathy appeared
and was surgically excised. Again, histopathological examination
revealed caseating gigantocellular granulomas and cultures were
negative. In January 2009, the patient appeared to be cured of TB.
3. Discussion
Clinical or radiological TB worsening, occurring at least four
weeks after starting anti-TB therapy, in a patient whose clinical
status initially improved, is known as a paradoxical reaction or
immune reconstitution syndrome (IRIS).1 It has been well
described in HIV patients with TB whose antiretroviral treatment
was started simultaneously with or within the ﬁrst few months of
the onset of anti-TB agents.2,3 It has also been observed in non-HIV-
infected patients.4 Different clinical pictures have been described,
including fever, lymphadenopathy, pulmonary inﬁltrates, pleurisy,
cerebral tuberculomas, and meningitis.2 Affected tissues have
usually contained granulomas, but cultures have been negative.2
This phenomenon has coincided with increased lymphocyte
counts and has been attributed to a hypersensitivity reaction to
antigens released by M. tuberculosis killed by anti-TB treatment;
this reaction reﬂects the rapid host immune reconstitution due to
the efﬁcacy of antiretroviral therapy.2,3
Inﬂiximab, a monoclonal antibody inhibitor of TNF-a, has been
used to treat spondylarthritis, but it has been shown to increase the
risk of TB because TNF-a is critical for the formation and
maintenance of granulomas, which prevent the systemic spread
of M. tuberculosis.
Our inﬂiximab-treated patient was diagnosed with active
miliary, splenic TB lesions, cerebral tuberculomas, and lymphade-
nopathies; her TB was probably latent and triggered by inﬂiximab.According to the guidelines,7,8 our patient with a TST result greater
than 5 mm should have received prophylactic treatment for TB
before inﬂiximab onset. Although the risk of TB during anti-TNF
therapy was known at that time, the threshold of the TST in France
for the treatment of latent TB was 10 mm.9 Nevertheless, this case
report highlights and reinforces the importance of the current
guidelines for assessing the risks and for managing M. tuberculosis
infection in patients due to start anti-TNF.
The inﬂiximab activity lasted 4–8 weeks; as a result IRIS
occurred over the next fewmonths after stopping inﬂiximab in the
presence of released TB antigens.1 The occurrence of a paradoxical
reaction after stopping inﬂiximab, when TB was diagnosed, has
previously been reported.1,5,6 Between 1999 and 2003, Garcia Vidal
et al.1 reviewed 284 inﬂiximab-treated patients in three Spanish
hospitals. Six (2.1%) of them had TB; of these, four (67%) developed
paradoxical reactions that occurred 5–16 weeks after TB.
Our patient presented unusually severe and prolonged para-
doxical reactions marked by several ﬂares during more than 14
months of follow-up; this is likely to reﬂect both a high antigenic
load and the strength of the immune reconstitution after
withdrawal of immunosuppression in an otherwise immunocom-
petent patient. Noncompliance, malabsorption, drug resistance,
and opportunistic infections were ruled out.
Paradoxical reactions are usually controlled by corticosteroids,
sometimes surgery, continuation of anti-TB treatment, and
withdrawal of anti-TNF.1,3 However, one case was recently
reported in which anti-TNF therapy (adalimumab) was resumed
to treat a life-threatening TB paradoxical reaction, with a prompt
favorable outcome.6 In another case, inﬂiximab was used to treat a
steroid-resistant TB paradoxical reaction involving the central
nervous system in a patient who had not previously been receiving
anti-TNF therapy.10 Thus maintenance inﬂiximab should be
considered to avoid dramatic paradoxical worsening.1,5,10
In summary, this case illustrates unusually prolonged and
severe TB paradoxical reactions precipitated by inﬂiximab
withdrawal and reinforces the importance of guidelines for
assessing and managing TB before starting anti-TNF.
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